| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

24-26 October 2022

BIO-Europe 2022

Leipzig

Germany

13-14 October 2022

HealthTech Innovation Days

Paris

France

11-12 October 2022

Brain Innovation Days

Brussels

Belgium

6-8 October 2022

AACR Special Conference: Cancer Epigenomics

Washington

WA

United States

6-7 October 2022

Iberian Digital Forum

5 October 2022

MSD European Business Development Outreach

Zurich

Switzerland

3-4 October 2022

Chardan's 6th Annual Genetic Medicines Conference

New York

NY

United States

3 October 2022

ORYZON to give updates on corporate progress in October

16 September 2022

ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

29 September - 1 October 2022

XIX Congress of the Spanish Society of Psychogeriatrics

Valladolid

Spain

Pagination

First page «
Previous page ‹
Page 19
Page 20
Page 21
Page 22
Current page 23
Page 24
Page 25
Page 26
Page 27
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel